Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac

Nuclear Medicine and Biology

Volumn 28, Issue 7, 2001, Pages 845-856

  Yordanov, A T ^a   Garmestani, K ^a   Zhang, M ^a   Zhang, Z ^a   Yao, Z ^b   Phillips, K E ^a   Herring, B ^a   Horak, E ^a   Beitzel, M P ^a   Schwarz, U P ^a   Gansow, O A ^a   Plascjak, P S ^b   Eckelman, W C ^b   Waldmann, T A ^a   Brechbiel, M W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

particle; Astatine; Monoclonal antibody; Radioimmunotherapy; SAPS

Indexed keywords

BIS(TRIBUTYLTIN) OXIDE; BROMINE DERIVATIVE; ESTER DERIVATIVE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; IODINE DERIVATIVE; N SUCCINIMIDYL 3 ASTATO 4 METHYLBENZOATE AT 211; N SUCCINIMIDYL 4 ASTATO 3 METHYLBENZOATE AT 211; N SUCCINIMIDYL 4 ASTATOBENZOATE AT 211; N SUCCINIMIDYL N (4 ASTATOPHENETHYL)SUCCINAMATE AT 211; N SUCCINIMIDYL N (4 ASTATOPHENETHYL)SUCCINAMATE IODINE I 125; ORGANOMETALLIC COMPOUND; PALLADIUM; UNCLASSIFIED DRUG;

ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CATALYST; CHEMICAL REACTION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; IN VIVO STUDY; ISOTOPE LABELING; LYMPHOMA; MOUSE; NONHUMAN; PLASMA CLEARANCE; RADIOIMMUNOTHERAPY;

ANIMALS; ANTIBODIES; ASTATINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; INDICATORS AND REAGENTS; ISOTOPE LABELING; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; RADIOPHARMACEUTICALS; RECEPTORS, INTERLEUKIN-2; SUCCINIMIDES; TISSUE DISTRIBUTION;

EID: 0034808003     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(01)00257-8     Document Type: Article

References (47)

1. The preparation of astatine labelled proteins
2. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A Phase I/II study
3. 211At-labelled monoclonal antibody to a sub-cutaneous human heterograft in the nude mouse II
4. Immunoconjugates, cancer therapeutics: Experimental and clinical agents
5. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor prolongs cardiac allograft survival
6. Tetrakis(triphenyphosphine)palladium(0)
7. Nitric acid oxidation of polyalkylbenzenes
8. Targeted antibodies in the treatment of lymphomas
9. Newer approaches to the radiolabeling of monoclonal antibodies by the use of metal chelates
10. 2 fragment
11. R, N-Succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: Synthesis and potential utility for the radioiodination of monoclonal antibodies
12. 225Ac as a source of α-particles in radioimmunotherapy
13. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
14. 211At-IgG conjugate which is stable in vivo
15. Nonuniformity of tumor dose in radioimmunotherapy
16. Synthesis and iodination of methyl 4-tri-n-butylstannylbenzoate, p-(methoxycarbonyl)phenylmercuric chloride and p-(methoxycarbonyl)phenylboronic acid
17. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders
18. Monoclonal antibody therapy of leukemia and lymphoma
19. 131I-anti-B1 (anti-CD20) antibody
20. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
21. Palladium-catalyzed reaction of aryl bromides with bis(tributyltin)
22. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity
23. Blocking [At-211]astatide accumulation in normal tissues: Preliminary evaluation of seven potential compounds
24. Radioimmunotherapy with alpha-emitting nuclides
25. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides
26. IL-2Rα-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Rα interaction
27. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas
28. Synthesis and in vivo comparison of antibody DTPA conjugates with different chemical bonds
29. A humanized antibody that binds to the interleukin 2 receptor
30. 211At]astato-3-pyridinecarboxylate
31. 211At produced in disposable internal and external bismuth targets
32. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II, Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells and on one of two types of helper T cells
33. Determination of the dissociation energy of the C-At bond in substituted astatobenzenes
34. 211At labelled lectins and antibodies-I
35. 211At labelled monoclonal antibody with known specificity in a murine system
36. The preparation of astatine labelled proteins using an electrophilic reaction
37. The biological behavior of some organic astatine compounds in rats
38. The reaction of astatine with aromatic diazonium compounds
39. Metabolism of immunoglobulins
40. The multichain interleukin-2 receptor: A target for immunotherapy in lymphoma
41. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac
42. Potential use of alpha emitting radionuclides in the treatment of cancer
43. Radioimmunotherapy: Recent results and future directions
44. Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha-particle radiotherapy
45. Phase I trial of astatine-211 labeled human/mouse chimeric anti-tenascin antibody administered into malignant brain tumor resection cavities
46. 2 fragments with the α-particle-emitting nuclide astatine-211: Preservation of immunoreactivity and in vivo localizing capacity
47. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an α-particle-emitting immunoconjugate